These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 38993881)

  • 1. Tacrolimus-why pharmacokinetics matter in the clinic.
    Henkel L; Jehn U; Thölking G; Reuter S
    Front Transplant; 2023; 2():1160752. PubMed ID: 38993881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus - Pharmacokinetic Considerations for Clinicians.
    Schutte-Nutgen K; Tholking G; Suwelack B; Reuter S
    Curr Drug Metab; 2018; 19(4):342-350. PubMed ID: 29298646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of tacrolimus metabolism rate on renal function after solid organ transplantation.
    Thölking G; Gerth HU; Schuette-Nuetgen K; Reuter S
    World J Transplant; 2017 Feb; 7(1):26-33. PubMed ID: 28280692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation.
    Gonzales HM; McGillicuddy JW; Rohan V; Chandler JL; Nadig SN; Dubay DA; Taber DJ
    Am J Transplant; 2020 Aug; 20(8):1969-1983. PubMed ID: 32406604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.
    Monchaud C; Marquet P
    Clin Pharmacokinet; 2009; 48(7):419-62. PubMed ID: 19691367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus Intrapatient Variability on Graft Outcomes in Adherent Renal Transplantation Patients: A Cross-Sectional Study.
    Nafar M; Keshtkari S; Ziaie S; Firouzan A; Borumandnia N; Dalili N; Poorrezagholi F; Samadian F; Samavat S
    Iran J Kidney Dis; 2024 May; 18(3):187-194. PubMed ID: 38904339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of extended-release tacrolimus twice a day might be beneficial for selected kidney transplant recipients: a case report.
    Füessl L; Kreuzer L; Nierychlewski K; Seibt T; Stangl MJ; Koliogiannis D; Meiser B; Schwarz M; Fischereder M; Kemmner S
    Front Med (Lausanne); 2024; 11():1336035. PubMed ID: 38988355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Low Tacrolimus Concentration-to-Dose Ratio Increases Calcineurin Inhibitor Nephrotoxicity and Cytomegalovirus Infection Risks in Kidney Transplant Recipients: A Single-Center Study in Japan.
    Tomizawa M; Hori S; Inoue K; Nishimura N; Nakai Y; Miyake M; Yoneda T; Fujimoto K
    Transplant Proc; 2023; 55(1):109-115. PubMed ID: 36623961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-center, open-label, randomized cross-over study to evaluate the pharmacokinetics and bioavailability of once-daily prolonged-release formulations of tacrolimus in de novo liver transplant recipients.
    Herden U; Sterneck M; Buchholz BM; Achilles EG; Ott A; Fischer L
    Immun Inflamm Dis; 2021 Dec; 9(4):1771-1780. PubMed ID: 34559956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.
    Thölking G; Siats L; Fortmann C; Koch R; Hüsing A; Cicinnati VR; Gerth HU; Wolters HH; Anthoni C; Pavenstädt H; Suwelack B; Schmidt HH; Kabar I
    Ann Transplant; 2016 Mar; 21():167-79. PubMed ID: 27003330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
    de Jonge H; Naesens M; Kuypers DR
    Ther Drug Monit; 2009 Aug; 31(4):416-35. PubMed ID: 19536049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
    Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients.
    Thongprayoon C; Hansrivijit P; Kovvuru K; Kanduri SR; Bathini T; Pivovarova A; Smith JR; Cheungpasitporn W
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32664531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
    Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
    Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis.
    Xie Q; Xiang Q; Liu Z; Mu G; Zhou S; Zhang Z; Ma L; Cui Y
    Curr Drug Metab; 2021; 22(10):758-771. PubMed ID: 34525930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.